TriangleNCT01283997 · OUTCOME
Change in the Mean Value of Patient-reported MD Anderson Symptom Inventory for Multiple Myeloma (MDASI-MM) Numbness Scores From Baseline to Week 10 Post Treatment.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- score on a scale
- Interval / dispersion
- Standard Deviation
- Time frame
- baseline and week 10
What was measured
Participants reported the severity of two cognitive symptoms numbness on a 0-10 scale, with 0 being 'not present' and 10 being 'as bad as you can imagine': Higher mean scores indicate more severe symptoms.
Analysis population: Participants with quantitative sensory testing (QST) done a week prior to the start of their minocycline treatment and with corresponding QST at week 10
Groups in this outcome
Placebo Group
Participants received one pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
Minocycline Group
Participants received minocycline 200 mg orally for 1 dose, then 100 mg orally every 12 hours for 10 weeks beginning at initiation of induction therapy for multiple myeloma
| Group | Source count |
|---|---|
| Placebo Group | 21 |
| Minocycline Group | 20 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Placebo Group | 1.38 | 2.36 | Not reported | Not reported | Not reported |
| Minocycline Group | 0.65 | 1.79 | Not reported | Not reported | Not reported |
Source statistical analyses
- ci Lower Limit
- -2.06
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 0.59
- group Description
- Difference in Numbness severity at baseline and week 10.
- group Ids
- OG000
- OG001
- non Inferiority Type
- OTHER
- p Value
- 0.56
- param Type
- Mean Difference (Final Values)
- param Value
- -0.73
- statistical Method
- Wilcoxon (Mann-Whitney)
Complete source fields
- analyses
- ci Lower Limit
- -2.06
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 0.59
- group Description
- Difference in Numbness severity at baseline and week 10.
- group Ids
- OG000
- OG001
- non Inferiority Type
- OTHER
- p Value
- 0.56
- param Type
- Mean Difference (Final Values)
- param Value
- -0.73
- statistical Method
- Wilcoxon (Mann-Whitney)
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 2.36
- value
- 1.38
- group Id
- OG001
- spread
- 1.79
- value
- 0.65
- denoms
- counts
- group Id
- OG000
- value
- 21
- group Id
- OG001
- value
- 20
- units
- Participants
- description
- Participants reported the severity of two cognitive symptoms numbness on a 0-10 scale, with 0 being 'not present' and 10 being 'as bad as you can imagine': Higher mean scores indicate more severe symptoms.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants received one pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
- id
- OG000
- title
- Placebo Group
- description
- Participants received minocycline 200 mg orally for 1 dose, then 100 mg orally every 12 hours for 10 weeks beginning at initiation of induction therapy for multiple myeloma
- id
- OG001
- title
- Minocycline Group
- param Type
- MEAN
- population Description
- Participants with quantitative sensory testing (QST) done a week prior to the start of their minocycline treatment and with corresponding QST at week 10
- reporting Status
- POSTED
- time Frame
- baseline and week 10
- title
- Change in the Mean Value of Patient-reported MD Anderson Symptom Inventory for Multiple Myeloma (MDASI-MM) Numbness Scores From Baseline to Week 10 Post Treatment.
- type
- SECONDARY
- unit Of Measure
- score on a scale
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice